Anne Jokilammi

This study identifies recurrent ERBB4 mutations with oncogenic potential and resistance to targeted therapies, suggesting clinical implications for treatment strategies.

This study uses phosphoproteomic analysis in zebrafish to show that ErbB inhibitors affect multiple signaling pathways, leading to similar physiological phenotypes.